



THE REPUBLIC OF UGANDA

**REPORT OF THE AUDITOR GENERAL ON THE FINANCIAL STATEMENTS OF
PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE (PHARMBIOTRAC)
CENTRE ACE II PROJECT
FOR THE YEAR ENDED 30TH JUNE 2020**

**OFFICE OF THE AUDITOR GENERAL
UGANDA**

TABLE OF CONTENTS

| | |
|--|----|
| LIST OF ACRONYMS | 2 |
| REPORT OF THE AUDITOR GENERAL ON THE AUDIT OF FINANCIAL STATEMENTS OF PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE (PHARMBIOTRAC) CENTRE ACE II PROJECT FOR THE YEAR ENDED 30TH JUNE, 2020 | 3 |
| Opinion | 3 |
| Basis for Opinion | 3 |
| Key Audit Matter | 3 |
| 1.0 Implementation of the Approved Budget | 4 |
| Other Information | 7 |
| The Accounting Officer Responsibilities for the Financial Statements | 7 |
| Auditor's Responsibilities for the audit of the Financial Statements..... | 8 |
| Other Reporting Responsibilities | 9 |
| Report on the audit of Compliance with Legislation..... | 9 |
| Appendix 1:..... | 10 |

LIST OF ACRONYMS

| Acronym | Meaning |
|----------------|--|
| BOU | Bank of Uganda |
| EGI | Electronic Government Information |
| F/Y | Financial Year |
| GOU | Government of Uganda |
| IEC | Information, Education and Communication |
| IESBA | International Ethics Standards Board for Accountants |
| INTOSAI | International Organization of Supreme Audit Institutions |
| IPF | Program Budgeting System |
| ISSA | International Standards on Auditing |
| MDA | Ministry, Department, and other Agencies |
| MOFA | Ministry of Foreign Affairs |
| MOFPED | Ministry of Finance, Planning and Economic Development |
| MOPS | Ministry of Public Service |
| NAA | National Audit Act |
| NTR | Non Tax Revenue |
| PBS | Program budgeting system |
| PFMA | Public Finance The Accounting Officer Act, 2015 |
| PHAMBIOTRAC | PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE |
| PS/ST | Permanent Secretary/Secretary to Treasury |
| TAI | Treasury Accounting Instructions |
| UGX | Uganda Shillings |
| USD | United States Dollar |

**REPORT OF THE AUDITOR GENERAL ON THE AUDIT OF FINANCIAL STATEMENTS OF
PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE (PHARMBIOTRAC) CENTRE
ACE II PROJECT FOR THE YEAR ENDED 30TH JUNE, 2020**

THE RT. HON. SPEAKER OF PARLIAMENT

Opinion

I have audited the accompanying financial statements of Pharm-Biotechnology And Traditional Medicine (Pharmbiotrac) Centre Ace II Project which comprise the statement of Financial Position as at 30th June 2020, and the Statement of Financial Performance, Statement of Changes in Equity and Statement of Cash Flows together with other accompanying statements for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In my opinion, the financial statements of Pharm-Biotechnology and Traditional Medicine (Pharmbiotrac) Centre Ace II Project for the year ended 30th June 2020 are prepared, in all material respects, in accordance with Section 51 of the Public Finance The Accounting Officer Act, 2015 and the Financial Reporting Guide, 2018.

Basis for Opinion

I conducted my audit in accordance with International Standards of Supreme Audit Institutions (ISSAIs). My responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of my report. I am independent of the Pharm-Biotechnology And Traditional Medicine (Pharmbiotrac) Centre Ace II Project in accordance with the Constitution of the Republic of Uganda, 1995 (as amended), the National Audit Act, 2008, the International Organization of Supreme Audit Institutions (INTOSAI) Code of Ethics, the International Ethics Standards Board for Accountants Code of Ethics for Professional Accountants (Parts A and B) (IESBA Code), and other independence requirements applicable to performing audits of Financial Statements in Uganda. I have fulfilled my other ethical responsibilities in accordance with the IESBA Code, and in accordance with other ethical requirements applicable to performing audits in Uganda. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

Key Audit Matter

Key audit matters are those matters that, in my professional judgment, were of most significance in my audit of the financial statements of the current period. These matters were addressed in the context of my audit of the financial statements as a whole, and in forming my opinion thereon, and I do not provide a separate opinion on these matters. I have determined the matter described below to be key audit matter communicated in my report.

1.0 Implementation of the Approved Budget

Every year, government plans and allocates funds to MDAs for implementation of activities that would enable the country to attain sustainable development. I observed that MDAs have challenges with regard to implementation of planned activities, which negatively affects service delivery and improvement of the people's wellbeing. As a result, the implementation of the approved budget was considered a key audit matter and during the office-wide planning, I identified risks common with MDAs which include; Inadequate Budgeting, under absorption of funds, Low Disbursement rate of Project funds, Shortfalls in achievement of Project Development Objectives

The Government of Uganda signed an agreement, dated March 17, 2017 with the World Bank through the International Development Association (IDA) for the financing of the Eastern and Southern Africa Higher Education Centres of Excellence Project (ACE II). MUST is the implementing Category 1 of the Project with a total Non-Refundable Grant of US\$ 6,000,000 channelled to the University by Government and also collaborating with Inter-University Council for East Africa (IUCEA) in carrying out Part 2 and 3 of the Project. The table below shows the allocation of project funds;

| Item | Amount | (USD) % age share |
|-------------------------------|------------------|----------------------|
| Learning | 2,450,309 | 40.8 |
| Research | 1,050,700 | 17.5 |
| Academic collaboration | 1,009,175 | 16.8 |
| Industry / sector partnership | 695,320 | 11.6 |
| M&E Administration | 794,496 | 13.2 |
| Total | 6,000,000 | 100.00 |

Source: Pharmbiotrac IFR Report as at 30th June 2020.

The Project Development Objective (PDO) for the ACE II project is to strengthen selected Eastern and Southern African higher education Institutions to deliver quality post-graduate education and build collaborative research capacity in the regional priority areas.

Pharmbiotrac aims to build a critical mass of specialized and skilled human resource that can advance traditional medicine and Pharm-Biotechnology for socio-economic development of Africa.

The outbreak of the Covid Pandemic affected the implementation of the 2019/20 budget especially activities in the last half of the financial year. As a result, a number of activities were not implemented due to budget cuts and lock down measures instituted to control the spread of the pandemic.

A review of the progress of project implementation revealed the following;

| No | Observation | Recommendation |
|-----|---|---|
| 1.1 | <p><u>Shortfalls in achievement of Project Development Objectives</u></p> <p>Section 8.4 of the African Center of Excellence (ACE) project operational manual requires the IUCEA/[RFU] to collect, analyse and submit status reports to the World Bank on the project performance. It further requires individual ACEs to collect and submit accurate data on the performance of each indicator in the agreed Results Framework to facilitate the RFU's.</p> <p>A review of the Pharmbiotrac Monitoring and Evaluation (M&E) Results Framework 1 Tracking Table for the period ended 30th June 2020 revealed shortfalls in a number of key Project Targets for the first 3 years.</p> <p>The Partially achieved targets include;</p> <ul style="list-style-type: none"> • Internationally recognized research publications in disciplines supported by the ACE Program and with regional coauthors • Reports by ACEs on Beneficiary Satisfaction <p>Details in Appendix 1.</p> <p>The shortfalls derail project implementation progress and may limit timely achievement of the intended project objectives.</p> <p>The Accounting Officer explained that the shortfalls in Short term courses was caused by delays in developing the curricular requiring adequate consultations of the communities. He further explained that implementation of the curricular was disrupted by the COVID 19 pandemic. He also explained that externally generated revenues were below the target as most of the project proposals submitted during the year under review did not receive funding.</p> | <p>I advised the Accounting Officer to institute appropriate mitigation measures to improve project implementation in line with the approved annual</p> |
| 1.2 | <p><u>Low Disbursement rate of Project funds</u></p> <p>During the review, it was noted that the 5 year project with total funding of USD.6million to MUST started in June 2017. A review of the statements revealed that a sum of only US\$.3,341,599 (76%) was disbursed in the 3 years period to 30th June 2020 against the planned cumulative expenditure of US \$ 4,398,018.</p> <p>The low disbursement rate implies that some funds are lying idle and this might impact on the attainment of the project objectives.</p> | <p>I advised the Accounting Officer and the project management to fast track planned activities linked indicators in line with the as disbursements are result based.</p> |

| | <p>The Accounting Officer acknowledged the anomaly. He however explained that the Inter-University Council for East Africa had approved an independent verifier for Disbursed Linked Indicators and this has since resulted in an improvement in the disbursements.</p> | | | | | | | | | | | | | | | | | | | | | |
|--------|--|---|---|-----------------|---------------|--------|--------|--|-------|---------|------------|--------|--------------------------------------|---|-------|---------|--|--------------|--------------|----------------|----------------|---|
| 1.3 | <p><u>Review of Annual Budget Performance (absorption of funds)</u></p> <p>A review of the Pharmbiotrac Monitoring and Evaluation (M&E) Results Framework 1 Tracking Table for the period ended 30th June 2020 revealed shortfalls in achievement of Project Targets for the first 3 years. I noted that Out of the total receipts for the financial year of USD. 1,677,853 only USD 1,473,238 was spent by the entity resulting in an unspent balance of USD 204,615 representing an absorption level of 88%. Appendix 1 refers.</p> <p>Under absorption of released funds resulted into non-implementation of planned activities such as;</p> <ul style="list-style-type: none">• Non Accredited education programs offered by the ACEs (Short term courses)• Failure to attract Students (national and regional) in ACEs: (i) Masters (No. of female) (ii) PhD (No. of female) (Short term) <p>The Accounting Officer explained that implementation of the planned activities was hampered by the abrupt closure of the University due to the outbreak of covid 19 pandemic.</p> | <p>I advised the Accounting Officer to ensure that activities which were not performed due to liaise with the funder and disruptions by COVID-19 are fast tracked in the subsequent period to enable objective assessment of performance.</p> | | | | | | | | | | | | | | | | | | | | |
| 1.4 | <p><u>Inadequate Budgeting</u></p> <p>A review of the Project's budgeted and actual expenditure revealed excess expenditure to the tune of US\$ 297,361 as shown in the table below;</p> <table><tr><th>Code</th><th>Expenditure Classification 1 as per the Project Implementation Plan</th><th>Bud get (US\$)</th><th>Actual (US\$)</th><th>Excess</th></tr><tr><td>5.2.14</td><td>Analytical Laboratory, purchase, installation, tear and wear</td><td>1,185</td><td>287,357</td><td>(286,172)</td></tr><tr><td>5.2.24</td><td>Joint follow up proposal development</td><td>-</td><td>8,819</td><td>(8,819)</td></tr><tr><td></td><td>TOTAL</td><td>1,185</td><td>296,176</td><td>297,361</td></tr></table> <p>Inadequate budgeting both in outputs and costs renders it difficult to adequately assess performance of the Project.</p> <p>The Accounting Officer explained that the over expenditure in 5.2.14 and 5.2.24 was because of priority of expenditure for results, since the project is a result based project which requires results achieved before money is disbursed. The project invested in activities that give results than those that don't produce results. He gave an example of students' enrolment as one of the key deliverables, purchases and installation of equipment was given a priority to enable</p> | Code | Expenditure Classification 1 as per the Project Implementation Plan | Bud get (US\$) | Actual (US\$) | Excess | 5.2.14 | Analytical Laboratory, purchase, installation, tear and wear | 1,185 | 287,357 | (286,172) | 5.2.24 | Joint follow up proposal development | - | 8,819 | (8,819) | | TOTAL | 1,185 | 296,176 | 297,361 | <p>I advised the Project The Accounting Officer to revise their Annual Targets for both Funding and outputs in the event of change of priorities.</p> |
| Code | Expenditure Classification 1 as per the Project Implementation Plan | Bud get (US\$) | Actual (US\$) | Excess | | | | | | | | | | | | | | | | | | |
| 5.2.14 | Analytical Laboratory, purchase, installation, tear and wear | 1,185 | 287,357 | (286,172) | | | | | | | | | | | | | | | | | | |
| 5.2.24 | Joint follow up proposal development | - | 8,819 | (8,819) | | | | | | | | | | | | | | | | | | |
| | TOTAL | 1,185 | 296,176 | 297,361 | | | | | | | | | | | | | | | | | | |

| | | |
|--|--|--|
| | students undertake their research and generate more DLI to fund the other project activities and to generate DLI 2.7. He further explained that the project chose to continuously invest in joint proposals by responding to calls which are spontaneous in nature hence over expenditure on joint proposal development. | |
|--|--|--|

Other Information

The Accounting Officer is responsible for the other information. The other information comprises the statement of responsibilities of the Accounting Officer and the commentaries by the Head of Accounts and the Accounting Officer, and other supplementary information. The other information does not include the financial statements and my auditors' report thereon. My opinion on the financial statements does not cover the other information and I do not express an audit opinion or any form of assurance conclusion thereon.

In connection with my audit of the financial statements, my responsibility is to read the other information and, in doing so, consider whether the other information is materially consistent with the financial statements or my knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work I have performed, I conclude that there is a material misstatement of this other information, I am required to report that fact. I have nothing to report in this regard.

The Accounting Officer Responsibilities for the Financial Statements

Under Article 164 of the Constitution of the Republic of Uganda, 1995 (as amended) and Section 45 of the Public Finance Management Act, 2015, the Accounting Officer is accountable to Parliament for the funds and resources of Ministry of East African Community Affairs.

The Accounting Officer is also responsible for the preparation of financial statements in accordance with the requirements of the Local Governments Financial and Accounting Manual, 2007 and the Public Finance Management Act, 2015 and for such internal control as management determines necessary to enable the preparation of financial statements that are free from material misstatement whether due to fraud or error.

In preparing the financial statements, the Accounting Officer is responsible for assessing the Ministry's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the Accounting Officer has a realistic alternative to the contrary.

The Accounting Officer is responsible for overseeing the Ministry of East African Community Affairs financial reporting process.

Auditor's Responsibilities for the audit of the Financial Statements

My objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISSAIs will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users, taken on the basis of these financial statements.

As part of an audit in accordance with ISSAIs, I exercise professional judgement and maintain professional scepticism throughout the audit. I also:-

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Ministry internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the The Accounting Officer.
- Conclude on the appropriateness of The Accounting Officer's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Ministry ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the Ministry to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

I communicate with the Accounting Officer regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

I also provide the Accounting Officer with a statement that I have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on my independence, and where applicable, related safeguards.

From the matters communicated with the Accounting Officer, I determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. I describe these matters in my auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, I determine that a matter should not be communicated in my report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Reporting Responsibilities

In accordance with Section 19 (1) of the National Audit Act, 2008, I report to you, based on my work described on the audit of Financial Statements, that; except for the matters raised in compliance with legislation section below, and whose effect has been considered in forming my opinion on financial statements, the activities, financial transactions and information reflected in the financial statements that have come to my notice during the audit, are in all material respects, in compliance with the authorities which govern them.

Report on the audit of Compliance with Legislation

There were no material findings in respect of the compliance criteria for the applicable subject matters to be reported.



John F.S. Muwanga
AUDITOR GENERAL

Appendix 1:

Achievement of Project Development Objectives

| Component | Indicator | Target July 2017-june 2020 | Actuals July 2017-June 2020 | Variance | |
|---|---|---|-----------------------------|----------|---------|
| Project Development Objectives | 1. Regional students enrolled in ACEs: (i) Masters (No. of Female) (ii) PhD (No. of female) | Masters (Total) | 9 | 20 | 11 |
| | | Masters (Female) | 3 | 11 | 8 |
| | | PhD (Total) | 6 | 9 | 3 |
| | | PhD (Female) | 2 | 2 | 0 |
| | | Short-term courses (Total) | 100 | 0 | -100 |
| | 2. Students (national and regional) enrolled in ACEs: (i) Masters (No. of female) (ii) PhD (No. of female) | Masters (Total) | 52 | 75 | 23 |
| | | Masters (Female) | 15 | 25 | 10 |
| | | PhD (Total) | 26 | 28 | 2 |
| | | PhD (Female) | 8 | 9 | 1 |
| | | Short-term courses (Total) | 530 | 0 | -530 |
| | 3. MOUs on partnerships for collaboration in applied research and training entered into by the ACEs | | 9 | 11 | 2 |
| | 4. Accredited education programs offered by the ACEs | Total | 4 | 4 | 0 |
| | | National | 4 | 4 | 0 |
| | | Regional | 0 | 0 | 0 |
| | | International | 0 | 0 | 0 |
| | | Short-term Courses | 1 | 0 | -1 |
| | 5. Direct Project Beneficiaries (of which female (students and staff) | Total | 113 | 139 | 26 |
| | | | 0 | | 0 |
| | | Female (%) | 31 | 40 | 9 |
| Component 1: Strengthening the Centres of Excellence in Regional Priority Areas | 1. Faculty and PhD students exchanges to promote research and teaching (No. of female) | Total | 36 | 40 | 4 |
| | | | 0 | | 0 |
| | | Female | 9 | 15 | 6 |
| | 2. Amount of externally generated revenue by the ACEs | | 620000 | | -492781 |
| | 3. Internationally recognized research publications in disciplines supported by the ACE Program and with regional coauthors | Total | 85 | 127,219 | -50 |
| | | No. co-authored with regional collaborators | 21 | 0 | -21 |
| Component 2: Capacity Building Support to ACEs | 1. Events that foster partnerships between ACE and private sector/industry | | 2 | 5 | 3 |
| | | | 0 | 0 | 0 |

| | | | | |
|--|--|----|----|----|
| through Regional Scholarship s | | | | |
| Component 3: Facilitation , Coordination and Administra tion of the Project Implement ation | 1. Knowledge sharing events with ACEs, partner institutions, academia and diaspora | 10 | 33 | 23 |
| | | 0 | 0 | 0 |
| | 2. Reports by ACEs on Beneficiary Satisfaction | 3 | 1 | -2 |
| | 3. Timely verification of ACE achievement of DLIs | 4 | 4 | 0 |
| | 4. Biannual reporting on M&E of the ACEs | 4 | 4 | 0 |

Source: Pharmbiotrac M&E Results Framework 1 Tracking Table



Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)

MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY

IMPLEMENTING ENTITY MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY

PROJECT NAME: PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE CENTRE(PHARMBIOTRAC)

REPORT: FINANCIAL REPORT YEAR ENDED 30/06/2020

PERIOD OF REPORT: PERIOD 1ST JULY 2019 TO 30TH JUNE 2020

REPORTING CURRENCY: UNITED STATES DOLLARS (USD)



Mbarara University of Science and Technology

Contents

| | |
|---|----|
| 1. STATEMENT OF RESPONSIBILITIES OF THE ACCOUNTING OFFICER | 3 |
| 2. General Information About PHARMBIOTRAC Project..... | 4 |
| The Project Development Objective | 4 |
| Background: | 4 |
| Objectives | 4 |
| Thematic areas of focus of PHARMBIOTRAC: | 5 |
| Key academic programs supported by PHARMBIOTRAC | 5 |
| Key achievements | 6 |
| 3. Commentary on the Financial Statements by the Finance Manager..... | 7 |
| 4. Statement of Sources and Uses of Funds..... | 9 |
| 5. Uses of Funds (Breakdown)..... | 10 |
| 6. Statement of Reimbursable Eligible Expenditure Programs (EEPs) | 13 |
| 7. DLI - ACHIEVED AS AT 30th June 2020..... | 14 |
| 8. POLICIES AND PROCEDURES..... | 15 |



1. STATEMENT OF RESPONSIBILITIES OF THE ACCOUNTING OFFICER

The Eastern and Southern Africa Higher Education Centres of Excellence project (ACH II) Financing Agreement requires the recipient through MoES to maintain a financial management system in accordance with the provisions of section 4.09 of the General conditions. The recipient shall cause Mbarara University of science and Technology to have their financial statements audited in accordance with the provision of section 4.09(b) of the general conditions,

Management accepts the responsibility for the financial statements, which have been prepared using appropriate accounting policies in conformity with the financing agreement and in the manner required by the World Bank guidelines for financial reporting and auditing of ACE II financed activities. Management also accepts the responsibility for safeguarding the assets of the project against fraud and other irregularities. Management further accepts the responsibility for the maintenance of accounting records which have been used in the preparation of the financial statements as well as adequate systems of internal financial control,


Financial statements have been prepared on cash basis accounting and comply with the generally accepted accounting practice for the public sector.

Nothing has come to the attention of management to indicate that any breakdown in the functioning of these controls resulting in loss of project funds has occurred during the year,

Management accepts the responsibility that the Project funds have been expended in accordance with the intended purposes as specified in the financing Agreement.

BYAMUHANA M. A. [Signature]
Accounting Officer (Names & Signature)

Date: 18/12/2022





2. General Information About PHARMBIOTRAC Project

The Eastern and southern Africa Higher Education centres of Excellence (ACE II) project supports the governments of eight participating countries - Ethiopia, Kenya, Malawi, Mozambique, Rwanda, Tanzania, Uganda and Zambia in strengthening the selected ACEs to deliver quality post-graduate education and build collaborative research capacity in the regional priority areas. In Uganda, the project is implemented by the MoES through Makerere University (MUK) with two centers, Uganda Martyrs University (UMU) and Mbarara University of Science and Technology (MUST).

The Project Development Objective

The Project Development Objective (PDO) is 'To strengthen selected Eastern and Southern African higher education institutions to deliver quality post-graduate education and build collaborative research capacity in the region priority areas.'

Background:

The Pharm-Biotechnology and Traditional Medicine Centre (PHARMBIOTRAC) is one of the 24 Eastern and Southern Africa Higher Education Centers of Excellence (ACE II) Program, and established at MUST in 2017 with the financial support from the World bank to a tune of 6 Million USD provided as a loan to the Government of Uganda and to MUST as "Non-Refundable Grant".

PHARMBIOTRAC is established in order to address one of the key development challenges facing Africa, i.e. low life expectancy and productivity compared to in other continents, majorly due to a high burden of both communicable and non-communicable diseases. The centre hopes to achieve this by use of Africa's rich biodiversity that forms the continent's natural wealth through providing a regional platform for innovative drug development, including exploring the use of traditional medicine in the region.

PHARMBIOTRAC provides support to selected highly motivated, research-focused and qualified candidates to pursue their MSc and PhD study programmes aimed at achieving the goal of the centre through the existing academic structures within MUST and departments that offer PHARMBIOTRAC relevant programmes.

The goal of PHARMBIOTRAC is "to build a critical mass of specialized and skilled human resource that can advance traditional medicine and Pharm-Biotechnology for socio-economic development of Africa".

Vision is "to be a leading African Centre of Excellence for training and research in traditional medicine and pharm-biotechnology",

Mission "to contribute to documentation, validation and value chain development of traditional medicine and biotechnology products for use in pharmaceutical and nutraceuticals industries in the region through training, research and community services for sustainable development".

Objectives

The main objective of PHARMBIOTRAC is to build a critical mass of specialized and skilled human resource that can advance traditional medicine and Pharm-Biotechnology for socio-economic development of Africa, and the specific objectives include to;


- strengthen capacity in the region to train highly skilled and specialized professionals in traditional medicine and Bio-pharmaceuticals,




Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)

- strengthen capacity in the region to engage in cutting edge research in TM and systems biology for health products development,
- create capacity in collaboration with private sector industry for development, production and commercialization of TM, biopharmaceuticals and nutraceuticals from research outputs,
- advance the practices of TM/TMK and promote domestication and sustainable utilization of medicinal species.

Governance structure of PHARMBIOTRAC



PHARMBIOTRAC Framework



Thematic areas of focus of PHARMBIOTRAC:

- Understanding Traditional Medicine Philosophy of Health and Disease Prevention and Control
- Traditional/Herbal Medicine Quality and Safety Standards
- Herbal Medicine Production/Manufacturing and Quality Control Standards
- Traditional/Herbal Medicine Knowledge and Material Conservation and Propagation - in-situ, ex situ
- Traditional/Herbal Medicine/ Clinical Validation Protocols and Standards
- Pharmaco-Biotechnology-Application of Biotechnology to Drug Discovery, and Drug Production
- Pharmaceutical Business Management/Regulation

Key academic programs supported by PHARMBIOTRAC

A: PhD by Research (thematic areas above) - Duration 3 years (31 students enrolled)

B: Current Masters programs offered (by course work and research) - Duration 2 years

Master of Science in Pharmacology (M.Pha)

Master of Science in Pharmacy (Clinical Pharmacy) (M.Sc. Clinical. Pharm.)



Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)

Master of Science in Pharmacognosy and Natural Medicine Science (M.Sc. PNMS)

Master of Science in Pharmaceutical Analysis under accreditation by National Council for Higher Education (Awaiting Accreditation).

Key achievements

- Developed three (3) new masters programs and 2 were accredited by NCHE for National accreditation:
 - Master of Science in Pharmacy (Clinical Pharmacy) (M.Sc. Clinical Pharm.) (currently 31 students enrolled),
 - Master of Science in Pharmacognosy and Natural Medicine Science (M.Sc. PNMS) (currently 18 students enrolled),
 - M Sc. in Pharmaceutical Analysis under accreditation by National Council for Higher Education (NCHE),
- Enrolment on other programme supported by PHARMBIOTRAC:
 - Master of Science in Pharmacology (currently 9 students enrolled)
- Attracted 5 scholarships every year for Clinical Pharmacy Masters Program from the Ministry of Health, Government of Uganda,
- PhD by research in PharmBiotechnology & Traditional Medicine (26 students enrolled),
- Short term course One (1) (Certificate in Traditional/herbal Medicine) was successfully developed (awaiting student recruitment)
- At least 30% of the enrolled students are regional students (outside Uganda)

Major procurements:

- 2 Project Vehicle procured (Bus and station wagon),
- Laboratory / Production equipment procured and installed,
- Laboratory / Biotechnology equipment procured and installed,
- ICT equipment procured and installed (Office and students),
- Office/student furniture procured (chairs, tables, cupboard),
- PHARMBIOTRAC Boardrooms furniture procured and installed,
- PHARMBIOTRAC Video Conferencing equipment procured and installed,
- PHARMBIOTRAC Living Gene Bank (Herbal Harden) secured and fencing of land-ongoing.

Major Publications of staff and students (Book Chapters and Journal Articles)

- 48 Journal article and 9 book chapters published



3. Commentary on the Financial Statements by the Finance Manager

1) Presentation currency

There reporting and presentation currency is the United States dollars (USD) in accordance to the donor requirements. Transactions in Uganda shillings have been converted to dollars using the transaction exchange rate at time of transfer. The Exchange rate as at 30th June 2020 was 3,655

1) Income

Total receipts during the period were USD 1,007,606 from World Bank IDA funds in accordance to the verification done. Other sources of income were students' fees USD 101, USD 58,595 from HIV study project, USD 250,000 from IUCEA – Incubation funds, USD 69,085 from ATRAP project and USD 5,036 from HARISSA project. Balance brought forward to the period was USD 287,430 providing total financing of USD 1,677,853.

2) Expenditure

Expenditure was USD 1,473,238 out of the total financing of USD 1,677,853 which was a performance of 88%. The performance was affected by suspension of activities due to COVID19 pandemic.

The major categories of expenditure were as follows:

i) 5.1 Action plan for learning excellence

Total expenditure on action plan for learning excellence was USD 315,136 for outputs of stipend for 31 PhD Students and 58 MSc students (USD 185,806), Equipment for ICT learning centre (61,385), contribution towards a research dissemination conference at MUST (USD 19,056), Community/industrial attachments (17,571) for 40 students, payment of tuition fees for 58 MSc students (8,971) and setting up traditional medicine clinics (5,836).

ii) 5.2 Action Plan for Research excellence

Total expenditure on this action plan was USD 746,246 in respect to purchase of research laboratory equipment (537,921.50), Research support for 31 PhD and 58 MSc students (100,408), staff research funds (29,981), staff participation in regional and international conferences (42,729) and staff attachment to foreign laboratories (9,294).

iii) 5.5 Action plan for attracting academic staff and students from the region

Expenditure was USD 68,592 for salaries of two recruited staff.

iv) 5.6 Action plan for National and Regional academic partners

Expenditure was USD 27,873 in respect to 1 visiting faculty member.

v) 5.8 Action plan for collaboration with international partners


Expenditure was USD 42,182 for 2 visiting professors who offered block lectures.

vi) 5.9 Action plan for management and Governance

Expenditure was USD 85,966 in respect to payment of salaries for 4 administrative staff, capacity building and meetings.

vii) 5.10 Action plan for sustainable financing

Expenditure was USD 39,370 in respect to payment of salary for the chair innovation and business management, for products exhibitions and students hand books.



I take full responsibility for the completeness and integrity of these Financial Statements (This was in the old commentary but not in your new, so I left it but highlights in another colour for your attention (either keep amend or remove).

.....Dominique Musara.....
Finance Manager [Names & Signature]

Date 18/12/2022




Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)

4. Statement of Sources and Uses of Funds

| MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY AFRICA HIGHER EDUCATION CENTERS OF EXCELLENCE PROJECT (126974) PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE CENTRE Statement of Sources and Uses of Funds for the annual period ending 30th June 2020 | | |
|---|---|----------------------------------|
| Sources of Fund | Annual Period ending From 1st. Jul.2019 to 30.Jun.2020 | Cummulative To Date 36 Months |
| Opening Cash Balance | | |
| Government Funds | - | - |
| World Bank IDA Funds | 271,319 | - |
| Student Fees | - | - |
| Partnership With SNV | 2,556 | - |
| IFS-Fund | 11,980 | - |
| Others-Hiv Study Project | 1,575 | - |
| ATRAP Project | - | - |
| HARISSA Project | - | - |
| IUCEA-Incubation Centre | - | - |
| Total | 287,430 | |
| Add Receipts | | |
| Government Funds | - | - |
| World Bank IDA Funds | 1,007,606 | 2,831,034 |
| Student Fees | 101 | 1,908 |
| Others-HIV Study Project | 58,595 | 169,999 |
| IUCEA-Incubation Centre | 250,000 | 250,000 |
| Partnership With SNV | - | 2,556 |
| ATRAP Project | 69,085 | 69,085 |
| HARISSA Project | 5,036 | 5,036 |
| IFS-Fund | - | 11,980 |
| Total Financing | 1,677,853 | 3,341,599 |
| Less: ACE Expenditure as per Project Implementation Plan | | |
| Expenditure Classification 1 PHARMBIOTRAC | 1,332,720 | 2,886,663 |
| Expenditure Classification 2 (HIV Study) | 46,191 | 155,994 |
| Expenditure Classification 3 Incubation centre | 5,866 | 5,866 |
| Expenditure Classification 4 ATRAP Project | 69,077 | 69,077 |
| Expenditure Classification 5 HARISSA Project | 4,826 | 4,826 |
| Expenditure Classification 6 SNV | 2,578 | 2,578 |
| Expenditure Classification 7 IFS | 11,980 | 11,980 |
| Total Uses of Funds by Components | 1,473,238 | 3,136,984 |
| Closing Balances | 204,615 | 204,614 |
| Bank of Uganda A/C 003370088400000 | 622 | 622 |
| Balance as per Stanchart Ugx A/C (0102808265800) | 12,940 | 12,940 |
| Balance as per Stanchart USD A/C (8702808265800) | 191,052 | 191,052 |
| Total Closing Cash Balance | 204,615 | 204,615 |

Prepared by Dominique Musuma
Finance and Administration Director

Approved by BYARUKA MUK
Accounting Officer





Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)

5. Uses of Funds (Breakdown)

| MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY- PHAMBIOTRAC PROJECT AFRICA HIGHER EDUCATION CENTERS OF EXCELLENCE PROJECT Uses of Funds (Breakdown) for the annual period ending 30th June 2020 (USD or FCFA) | | | | | | | |
|---|---|---------|----------|--|-----------|----------|--|
| Expenditure | Annual Period ending From 1st July, 2019- 30th June 2020 | | | Cumulative To date 36 Months Planned Cumulative For 3 | | | Explanation of Variance |
| | Actual | Planned | Variance | Actual | Planned | Variance | |
| Expenditure Classification 1 as per Project Implementation Plan | | | | | | | |
| 5.1 Action Plan for Learning Excellence | | | | | | | |
| 5.1.1 Benchmarking visits (India) | 0 | 0 | 0 | 31,788 | 35,360 | 3,572 | Activity Completed |
| Benchmarking visits (South Africa) | 0 | 0 | 0 | 31,088 | 29,290 | -1,798 | Activity Completed |
| 5.1.3 Benchmarking visits (USA) | 0 | 0 | 0 | 38,740 | 37,995 | -745 | Activity Completed |
| 5.1.4 Establishment of learning teams | 0 | 1,000 | 1,000 | 4,197 | 3,000 | -1,197 | students were taken than planned. |
| 5.1.5 Installation of ICT systems for learning | 11,385 | 3,000 | -8,385 | 11,385 | 16,000 | 4,615 | Activity Completed |
| 5.1.6 Curriculum development (Short courses MSc & PhD) | 0 | 0 | 0 | 22,758 | 20,400 | -2,358 | Activity Completed |
| 5.1.7 Curriculum accreditation (Fast Track fees) | 0 | 0 | 0 | 19,263 | 16,000 | -3,263 | Activity Completed |
| 5.1.8 Students Hand Books (PHD & Masters) | 0 | 340 | 340 | 0 | 1,020 | 1,020 | Activity still on going |
| 5.1.9 Learning materials (lecturers reference materials, demonstration materials etc.) | 2,789 | 6,000 | 3,211 | 5,048 | 18,000 | 12,952 | The process is still on going. |
| 5.1.10 Upgrading Learning Facilities Pharmacy (production unit) | 0 | 0 | 0 | 0 | 70,000 | 70,000 | Activity was put on Hold due unavailability of funds. |
| 5.1.11 Lecture room upgrade | 957 | 0 | -957 | 5,485 | 12,000 | 6,515 | Activity still on going. |
| 5.1.12 Digital Library / ICT learning centre / video conferencing facilities/ computer workstations for students | 50,000 | 2,500 | -47,500 | 50,578 | 55,000 | 4,422 | ICT Equipment for students has been finalised |
| 5.1.13 Standby generator (purchase & installation) | 0 | 0 | 0 | 0 | 10,000 | 10,000 | Activity was put on Hold due unavailability of funds. |
| 5.1.14 Fuel and maintenance | 2,729 | 3,600 | 871 | 2,729 | 10,800 | 8,071 | Expenditure still on going |
| 5.1.15 Chair Learning Excellence coordination | 0 | 660 | 660 | 0 | 1,980 | 1,980 | Activity still on going. |
| 5.1.16 Advertisement/ assembling of trainers/ recruitment of students for short courses and training | 0 | 2,500 | 2,500 | 0 | 7,500 | 7,500 | Activity Completed |
| 5.1.17 Advertisement/ assembling, recruitment of students for MSc and PhD. and training | 0 | 2,500 | 2,500 | 12,992 | 7,500 | -5,492 | Activity Completed |
| 5.1.18 Facilitation for industry experts / practitioners (10 ppl) | 0 | 13,800 | 13,800 | 7,196 | 32,100 | 24,904 | The activity is still on going |
| 5.1.19 Tuition Fee PhD | 0 | 90,000 | 90,000 | 97,526 | 180,000 | 82,474 | Expenditure still on going |
| 5.1.20 Tuition Fee MSc | 8,971 | 48,000 | 39,029 | 14,642 | 120,000 | 105,358 | Expenditure still on going |
| 5.1.21 Traditional Medicine Clinics setup and maintenance | 5,836 | 20,000 | 14,164 | 5,836 | 60,000 | 54,164 | Activity still on going. |
| 5.1.22 Stipend PhD (annually) | 122,800 | 135,000 | 12,200 | 396,654 | 270,000 | -126,654 | More Phd students were recruited in the First year than earlier planned. The excess expenditure will be absorbed in subsequent years |
| 5.1.23 Stipend MSc (annually) | 63,006 | 60,000 | -3,006 | 157,166 | 150,000 | -7,166 | Expenditure still on going |
| 5.1.24 Travel (Flights) for Students (return flights) | 2,916 | 4,800 | 1,884 | 22,855 | 14,400 | -8,455 | This expenditure was initially under estimated. However its being allocated |
| 5.1.25 External examiners | 0 | 1,500 | 1,500 | 0 | 4,500 | 4,500 | Activity Planned for |
| 5.1.26 meeting | 19,056 | 43,400 | 24,344 | 41,685 | 86,800 | 45,115 | Activity still on going. |
| 5.1.27 Student presentation at national conferences | 280 | 5,000 | 4,720 | 1,727 | 12,500 | 10,773 | Activity still on going. |
| 5.1.28 Student presentation at regional conferences | 0 | 3,000 | 3,000 | 340 | 6,000 | 5,660 | Activity still on going. |
| 5.1.29 Student presentation at international conferences | 5,446 | 4,800 | -646 | 6,653 | 9,200 | 2,547 | Activity still on going. |
| 5.1.30 Community / Industry attachments (Masters) | 17,571 | 13,800 | -3,771 | 18,936 | 34,500 | 15,564 | Activity still on going. |
| 5.1.31 Community / Industry attachments (PhD) | 0 | 20,400 | 20,400 | 1,800 | 40,800 | 39,000 | Activity still on going. |
| 5.1.32 30 Seater Bus | 0 | 0 | 0 | 73,557 | 50,000 | -23,557 | Activity Completed |
| 5.1.33 Bus (fuel and maintenance) | 1,121 | 7,200 | 6,079 | 1,564 | 21,800 | 20,236 | Expenditure still on going |
| 5.1.34 Medical emergency fund / First Aid kit | 273 | 1,000 | 727 | 1,340 | 3,000 | 1,660 | Expenditure still on going |
| 5.1.35 Students accomodation | 0 | 0 | 0 | 12,045 | 0 | -12,045 | This expenditure was not budgeted for. However it became necessary at implimentation as international students needed to be accomodated. |
| Sub Total | 315,136 | 493,600 | 178,464 | 1,097,552 | 1,447,245 | 349,693 | |
| Expenditure Classification 2 as per Project Implementation Plan | | | | | | | |
| 5.2 Action Plan for Research Excellence | | | | | | | |
| 5.2.1 Research Policy and Plan draft development (Y1 development Y4 review) | 0 | 1,980 | 1,980 | 0 | 6,600 | 6,600 | Expenditure Still on going |
| 5.2.2 Research Policy and Plan finalisation (Y1 development Y4 review) | 0 | 17,650 | 17,650 | 0 | 35,300 | 35,300 | Expenditure Still on going |
| 5.2.3 Staff attachments to foreign laboratories WPI (USA) | 9,294 | 7,775 | -1,519 | 15,889 | 23,325 | 7,436 | Expenditure Still on going |



Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)

| | | | | | | | | |
|--|---|----------------|----------------|-----------------|----------------|------------------|----------------|--|
| 5.2.4 | Staff attachments to foreign laboratories IHST (India) | 0 | 5,550 | 5,550 | 8,118 | 16,650 | 8,534 | Expenditure Still on going |
| 5.2.5 | Staff attachments to foreign laboratories KEMRI (Kenya) | 610 | 15,600 | 14,990 | 6,410 | 46,800 | 40,390 | Expenditure Still on going |
| 5.2.6 | Staff attachments to foreign laboratories Gezira (Sudan) | 0 | 16,050 | 16,050 | 0 | 48,150 | 48,150 | Expenditure Still on going |
| 5.2.7 | Establishment of Living gene bank (Garden) - MUST | 1,625 | 0 | -1,625 | 5,364 | 26,000 | 20,636 | Expenditure Still on going |
| 5.2.8 | Staff research funds | 29,981 | 15,000 | -14,981 | 29,981 | 50,000 | 20,019 | Expenditure Still on going |
| 5.2.9 | Staff participation in regional conference | 14,873 | 14,550 | -323 | 24,963 | 43,650 | 18,687 | Activity still on going |
| 5.2.10 | Staff participation in international conference | 27,856 | 17,600 | -10,256 | 41,956 | 52,800 | 10,844 | Activity still on going |
| 5.2.11 | Germplasm collection missions (MUST) | 0 | 11,000 | 11,000 | 0 | 33,000 | 33,000 | Activity still on going |
| 5.2.12 | Pharm-Biotech laboratory equipment purchase, installation, tear and wear | 94,500 | 945 | -93,555 | 94,500 | 96,390 | 1,890 | Purchase of Lab Equipment was completed |
| 5.2.13 | Product development laboratory, purchase, installation, tear and wear | ##### | 1,886 | -154,179 | 156,642 | 192,372 | 35,730 | Purchase of Lab Equipment was completed |
| 5.2.14 | Analytical Laboratory, purchase, installation, tear and wear | 287,357 | 1,185 | -286,172 | 287,357 | 120,870 | -166,487 | Purchase of Lab Equipment was completed |
| 5.2.15 | Journal Publication fee (Open Access) | 1,275 | 15,000 | 13,725 | 1,945 | 42,500 | 40,555 | Activity still on going |
| 5.2.17 | Monographs (Product Monographs) | 0 | 6,000 | 6,000 | 0 | 18,000 | 18,000 | Activity still on going |
| 5.2.18 | Masters Seminars | 0 | 1,860 | 1,860 | 0 | 5,580 | 5,580 | Activity still on going |
| 5.2.19 | Doctoral Seminars | 0 | 1,860 | 1,860 | 3,166 | 5,580 | 2,414 | Activity still on going |
| 5.2.20 | Supervision fee (Masters) | 0 | 750 | 750 | 0 | 1,500 | 1,500 | Activity still on going |
| 5.2.22 | Supervision fee field (Masters) (3 days / semester) | 178 | 6,000 | 5,823 | 178 | 15,000 | 14,823 | Activity still on going |
| 5.2.23 | Supervision fee fee (PhD) (3 days/ semester) | 1,742 | 4,000 | 2,258 | 1,742 | 10,000 | 8,258 | Activity still on going |
| 5.2.24 | Joint follow up proposal development | 8,819 | 0 | -8,819 | 16,371 | 7,450 | -8,521 | Activity still on going |
| 5.2.25 | Chair Research Excellence coordination | 161 | 660 | 499 | 161 | 1,980 | 1,819 | Activity still on going |
| 5.2.26 | Research support for MSc students | 4,698 | 21,000 | 16,302 | 6,783 | 63,000 | 56,217 | Activity still on going |
| 5.2.27 | Research support for PhD students | 95,710 | 135,000 | 39,290 | 115,593 | 270,000 | 154,407 | Activity still on going |
| 5.2.28 | Station wagon purchase (4 wheel drive) | 0 | 0 | 0 | 75,993 | 100,000 | 24,007 | The activity was finalized. The balance was allocated to the purchase of a 32 seater Bus |
| 5.2.29 | Fuel and maintenance for Station wagon (4 wheel drive) | 6,009 | 16,800 | 10,791 | 10,899 | 50,400 | 39,501 | Activity still on going |
| 5.2.30 | Laboratory technician | 5,493 | 6,000 | 507 | 16,478 | 18,000 | 1,522 | Activity still on going |
| | Sub Total | 746,246 | 347,701 | -398,545 | 920,489 | 1,406,897 | 486,408 | |
| Expenditure Classification 3 as per Project Implementation Plan | | | | | | | | |
| 5.3 | ACE Action Plan for Quality Assurance | | | | | | | |
| 5.3.1 | Quality Assurance and M&E consultancy | 0 | 4,000 | 4,000 | 0 | 12,000 | 12,000 | Activity Planned for |
| 5.3.2 | Chair Learning and Research Quality Assurance | 0 | 660 | 660 | 0 | 1,980 | 1,980 | Activity Planned for |
| 5.3.3 | Tracer studies | 53 | 3,000 | 2,947 | 3,561 | 9,000 | 5,439 | Activity still on going |
| | Sub Total | 53 | 7,660 | 7,607 | 3,561 | 22,980 | 19,419 | |
| Expenditure Classification 4 as per Project Implementation Plan | | | | | | | | |
| 5.4 | ACE Action Plan regarding Equity Dimensions | | | | | | | |
| 5.4.1 | Access audit | 0 | 0 | 0 | 0 | 2,000 | 2,000 | Expenditure Put on hold |
| 5.4.2 | Facility upgrade | 0 | 0 | 0 | 0 | 4,000 | 4,000 | Expenditure Put on hold |
| | Sub Total | 0 | 0 | 0 | 0 | 6,000 | 6,000 | |
| Expenditure Classification 5 as per Project Implementation Plan | | | | | | | | |
| 5.5 | ACE Action Plan for Attracting Academic Staff and Students from the Region | | | | | | | |
| 5.5.1 | Dissemination of Research Policy to attract academic staff of the region | 0 | 1,000 | 1,000 | 0 | 3,000 | 3,000 | Expenditure Put on hold |
| 5.5.2 | Language learning support | 0 | 3,000 | 3,000 | 0 | 9,000 | 9,000 | The activity was dropped. To be implemented by the University for all students |
| 5.5.3 | Recruited staff salaries (2 senior lecturers) | 68,592 | 48,000 | -20,592 | 143,662 | 144,000 | 338 | Expenditure still on going. |
| | Sub Total | 68,592 | 52,000 | -16,592 | 143,662 | 156,000 | 12,338 | |
| Expenditure Classification 6 as per Project Implementation Plan | | | | | | | | |
| 5.6 | ACE Action Plan for National and Regional Academic Partners | | | | | | | |
| 5.6.1 | Regional Visiting faculty members - Kenya | 3,751 | 7,410 | 3,659 | 4,899 | 22,230 | 17,331 | Activity still on going |
| 5.6.2 | Regional Visiting faculty members - South Africa | 2,350 | 7,410 | 5,060 | 2,350 | 22,230 | 19,880 | Activity still on going |
| 5.6.3 | Regional Visiting faculty members - Sudan | 12,238 | 7,410 | -4,828 | 26,665 | 22,230 | -4,435 | Activity still on going |
| 5.6.4 | Regional Visiting faculty members - Mozambique | 6,915 | 7,410 | 495 | 6,915 | 22,230 | 15,315 | Activity still on going |
| 5.6.5 | National Visiting faculty members - BSU | 0 | 2,960 | 2,960 | 0 | 8,880 | 8,880 | Activity still on going |
| 5.6.6 | National Visiting faculty members - Makerere | 2,620 | 3,260 | 640 | 4,121 | 9,780 | 5,659 | Activity still on going |
| 5.6.7 | National Visiting faculty members - UTAMU | 0 | 3,260 | 3,260 | 0 | 9,780 | 9,780 | Activity still on going |
| 5.6.8 | National Visiting faculty members - Gulu University | 0 | 3,460 | 3,460 | 0 | 10,380 | 10,380 | Activity still on going |
| 5.6.9 | Student attachment African Partner - KEMRI - Kenya | 0 | 23,750 | 23,750 | 0 | 66,500 | 66,500 | Activity still on going |
| 5.6.10 | Student attachment African Partner - Gezira University - Sudan | 0 | 26,250 | 26,250 | 0 | 73,500 | 73,500 | Activity still on going |
| 5.6.11 | Establishment of Living gene bank (Garden) - BSU/GU | 0 | 0 | 0 | 0 | 26,000 | 26,000 | Activity still on going |
| 5.6.12 | Germplasm collection maintenance (BSU) | 0 | 4,060 | 4,060 | 0 | 12,180 | 12,180 | |
| 5.6.13 | Germplasm collection maintenance (Gulu University) | 0 | 4,060 | 4,060 | 3,605 | 12,180 | 8,575 | Activity still on going |
| | Sub Total | 27,873 | 100,700 | 72,827 | 48,555 | 318,100 | 269,545 | |
| Expenditure Classification 7 as per Project Implementation Plan | | | | | | | | |
| 5.7 | ACE Action Plan for National and Regional Sector Partners | | | | | | | |
| 5.7.1 | Community training kits | 3,021 | 6,300 | 3,279 | 8,685 | 18,900 | 10,215 | Activity Still on going |
| 5.7.2 | Training Centre (Traditional Medical Practitioners) BUMETHA | 2,698 | 400 | -2,298 | 2,698 | 10,800 | 8,102 | Activity Still on going |
| 5.7.3 | Training Centre (Traditional Medical Practitioners) IACM | 0 | 400 | 400 | 0 | 10,800 | 10,800 | Activity Still on going |




Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)

| | | | | | | | | |
|---|---|------------------|------------------|----------------|------------------|------------------|------------------|---|
| 5.7.4 | Training Centre (Traditional Medical Practitioners) THETA-Uganda | 1,582 | 400 | -1,182 | 2,873 | 10,800 | 7,927 | Activity Still on going |
| 5.7.5 | Training Centre (Traditional Medical Practitioners) ANAMED | 0 | 400 | 400 | 0 | 10,800 | 10,800 | Activity Still on going |
| 5.7.6 | Training Centre (Traditional Medical Practitioners) NCRL centre | 0 | 400 | 400 | 0 | 10,800 | 10,800 | Activity Still on going |
| | Sub Total | 7,302 | 8,300 | 998 | 14,257 | 72,900 | 58,643 | Activity Still on going |
| Expenditure Classification 8 as per Project Implementation Plan | | | | | | | | |
| 5.8 | ACE Action Plan for Collaboration with International Academic Partners | | | | | | | |
| 5.8.1 | International Visiting faculty members (USA) | 8,984 | 9,090 | 106 | 8,984 | 27,270 | 18,286 | Activity still on going |
| 5.8.2 | International Visiting faculty members (India) | 2,011 | 7,490 | 5,479 | 4,318 | 22,470 | 18,152 | Activity still on going |
| 5.8.3 | Sabbatical Place (6 months per year) | 31,186 | 21,300 | -9,886 | 52,572 | 63,900 | 11,328 | Activity still on going |
| | Sub Total | 42,182 | 37,880 | -4,302 | 65,875 | 113,640 | 47,765 | |
| Expenditure Classification 9 as per Project Implementation Plan | | | | | | | | |
| 5.9 | ACE Action Plan for Management and Governance | | | | | | | |
| 5.9.1 | Establishment of PHARMBIOTRAC secretariat | 0 | 0 | 0 | 21,739 | 23,000 | 1,261 | Activity was finalised. |
| 5.9.2 | Installation of ICT systems for finance & administration | 594 | 0 | -594 | 3,375 | 5,000 | 1,625 | Activity was finalised. |
| | | | | | | | | Meeting took place in both Mbarara and Kampala instead of Mbarara only as planned. The Kampala meeting was mandated by MoE Which resulted into an expected costs. |
| 5.9.3 | Inception and planning meeting of all partners | 0 | 0 | 0 | 57,089 | 35,736 | -21,353 | Activity Still on going |
| 5.9.4 | Meeting of Steering Committee | 442 | 9,060 | 8,618 | 2,856 | 27,180 | 24,324 | Initially the meeting was planned for a small team. However the University council required all committee members to attend the meeting which exceeded the planned expenditure. |
| 5.9.5 | Meeting of Executive Committee | 0 | 1,140 | 1,140 | 3,694 | 3,420 | -274 | This activity was under Budgeted. |
| 5.9.6 | Meeting of Finance & Administration committee | 0 | 480 | 480 | 7,430 | 1,440 | -5,990 | More activities were involved than what was initially budgeted. To be recovered from other activities |
| 5.9.7 | Core Team Project review and planning meeting | 2,061 | 5,550 | 3,489 | 23,344 | 16,650 | -6,694 | Activity still on going |
| 5.9.8 | PHARMBIOTRAC meetings with WB & IUCEA | 3,247 | 3,920 | 673 | 8,469 | 11,760 | 3,291 | Activity still on going |
| 5.9.9 | Bi-Annual Meeting by IUCEA | 3,444 | 24,040 | 20,596 | 56,285 | 72,120 | 15,835 | Activity still on going |
| 5.9.10 | Staff orientation workshop | 0 | 0 | 0 | 1,718 | 1,000 | -718 | Activity was under budgeted |
| 5.9.11 | PHARMBIOTRAC Administrator | 0 | 24,000 | 24,000 | 32,022 | 72,000 | 39,978 | Activity Still on going |
| 5.9.12 | PHARMBIOTRAC Administrative Assistant | 5,493 | 6,000 | 507 | 16,977 | 18,000 | 1,023 | Activity Still on going |
| 5.9.13 | PHARMBIOTRAC Accountant | 21,998 | 24,000 | 2,002 | 64,005 | 72,000 | 7,995 | Activity Still on going |
| 5.9.14 | PHARMBIOTRAC Procurement Assistant / Secretary | 5,493 | 6,000 | 507 | 16,478 | 18,000 | 1,522 | Activity Still on going |
| 5.9.15 | Partner coordination / supervision visits regional (2 ppl) | 3,780 | 23,840 | 20,060 | 40,640 | 55,560 | 24,920 | Activity Still on going |
| 5.9.16 | Driver | 2,747 | 3,000 | 253 | 8,240 | 9,000 | 760 | Activity Still on going |
| 5.9.17 | Cleaner | 2,190 | 2,400 | 210 | 6,570 | 7,200 | 630 | Activity Still on going |
| 5.9.18 | Office supplies | 3,102 | 1,800 | -1,302 | 7,511 | 5,400 | -2,111 | Activity Still on going |
| 5.9.19 | Capacity building | 27,363 | 100,000 | 72,637 | 84,649 | 138,140 | 53,491 | Activity Still on going |
| 5.9.20 | In land travels | 3,492 | 15,000 | 11,508 | 12,879 | 15,000 | 2,121 | Activity Still on going |
| 5.9.21 | Communication | 293 | 6,600 | 6,307 | 717 | 6,600 | 5,883 | Activity Still on going |
| 5.9.22 | Recruitment of staff | 0 | 10,000 | 10,000 | 6,482 | 10,000 | 3,518 | Activity Still on going |
| 5.9.23 | Bank charges | 352 | 2,000 | 1,648 | 597 | 2,000 | 1,403 | Activity Still on going |
| 5.9.24 | Exchange gain/Losses | -125 | 0 | 125 | 1,866 | 0 | -1,866 | Exchanges losses recognised as a result of operating different currencies. |
| | Sub Total | 85,966 | 268,830 | 182,864 | 485,634 | 636,206 | 150,572 | |
| Expenditure Classification 10 as per Project Implementation Plan | | | | | | | | |
| 5.10 | ACE Action Plan for Sustainable Financing | | | | | | | |
| 5.10.1 | Chair Innovation & Business Management | 27,467 | 30,000 | 2,533 | 77,407 | 90,000 | 12,593 | Expenditure Still on going |
| 5.10.2 | Business clinic (furniture, computer, software) | 5,369 | 880 | -4,489 | 5,369 | 10,560 | 5,191 | Expenditure Still on going |
| 5.10.3 | Product exhibitions (Regional) | 1,840 | 5,200 | 3,360 | 11,845 | 15,600 | 3,756 | Activity is still on going |
| 5.10.4 | Product exhibitions (National) | 3,061 | 2,280 | -781 | 4,816 | 6,840 | 2,024 | Activity is still on going |
| 5.10.5 | Chair innovation & Business Management Meetings | 0 | 660 | 660 | 110 | 1,980 | 1,870 | Activity is still on going |
| 5.10.6 | Student handbooks (in-service professionals short course) | 420 | 1,000 | 580 | 420 | 3,000 | 2,580 | Activity is still on going |
| 5.10.7 | Student handbooks (short course for TMPs) | 0 | 5,000 | 5,000 | 0 | 15,000 | 15,000 | Activity is still on going |
| 5.10.8 | Business clinic coordination & branding | 1,214 | 15,600 | 14,387 | 5,576 | 46,800 | 41,224 | Activity is still on going |
| | Sub total | 39,370 | 60,620 | 21,250 | 105,542 | 189,780 | 84,238 | |
| Expenditure Classification 11 as per Project Implementation Plan | | | | | | | | |
| 5.11 | ACE Action Plan for Monitoring and Evaluation | | | | | | | |
| 5.11.1 | Strategic plan draft development | 0 | 0 | 0 | 0 | 4,620 | 4,620 | Activity Still on going |
| 5.11.2 | Strategic plan finalisation | 0 | 0 | 0 | 1,538 | 11,650 | 10,112 | Activity Still on going |
| 5.11.3 | M&E Missions (Internal) | 0 | 4,000 | 4,000 | 0 | 12,000 | 12,000 | Activity Still on going |
| | Sub Total | 0 | 4,000 | 4,000 | 1,538 | 28,270 | 26,732 | |
| Grand Total Uses of Funds | | 1,332,720 | 1,381,291 | 48,571 | 2,886,663 | 4,398,018 | 1,511,355 | |

Prepared by: *Somlingo Musingu*
Finance and Administration Director

Approved by: *BIASUCHANZA NICE*
Accounting Officer





Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)

6. Statement of Reimbursable Eligible Expenditure Programs (EEPs)


| MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY AFRICA HIGHER EDUCATION CENTERS OF EXCELLENCE PROJECT (126974) Statement of Reimbursable Eligible Expenditure Programs (EEPs) for the annual period ending 30th June 2020 | | |
|---|--|-------------------------------------|
| Eligible Expenditure Program (EEP) | Annual Period ending...30th June 2020 | Cummulative Todate For 36 months |
| EEP 1: Salaries | 8,979,069 | 53,874,414.05 |
| EEP 2: Non Procurable Expenditure as defined in Financing Agreement | 473,961 | 1,806,672.96 |
| Total EEPs | 9,453,030 | 55,681,087 |

Note.

Exchange rate used 3655

Prepared by Dominique Nwama
Finance and Administration Director

Approved by Byamuhanga M. K. M. K.
Accounting Officer





Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)


7. DLI - ACHIEVED AS AT 30th June 2020

MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY
PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE CENTRE
AFRICA HIGHER EDUCATION CENTERS OF EXCELLENCE PROJECT (126974)
DLI - ACHIEVED AS AT 30th June 2020

| DISBURSEMENT LINKED TO INDICATORS | ACTIONS TO BE COMPLETED | AMOUNT ALLOCATED | AMOUNT DISBURSED | Amount Disbursed After the reporting Date | Cummulative Amount Earned/ Disbursed | UN- DISBURSED BALANCE |
|--|--|------------------|------------------|---|--------------------------------------|-----------------------|
| DLI1: Institutional readiness | DLR 1.1: To meet Conditions for Effectiveness | 600,000 | 600,000 | - | 600,000 | - |
| | DLR 1.2: Development of detailed implementation plans | 500,000 | 500,000 | - | 500,000 | - |
| DLI 2: Excellence in education and research capacity and development impact | DLR 2.1: Timely annual implementation of the plans | 500,000 | - | - | - | 500,000 |
| | DLR 2.2: Newly enrolled students in the ACE of which at least 20% must be regional (African) students Short Course: Female Ugandans (national) | 1,200,000 | 594,000 | - | 594,000 | 606,000 |
| | Short Course: Male Ugandan students | | | | - | - |
| | Short Course: Female regional (African) students | | | | - | - |
| | Short Course: Male regional (African) students | | | | - | - |
| | MSC: Female Ugandan students | | | | - | - |
| | MSC: Male Ugandan students | | | | - | - |
| | MSC: Female regional (African) students | | | | - | - |
| | MSC: Male regional (African) students | | | | - | - |
| | PhD: Female Ugandan students | | | | - | - |
| | PhD: Male Ugandan students | | | | - | - |
| | PhD: Female regional (African) students | | | | - | - |
| | PhD: Male regional (African) students | | | | - | - |
| | DLR 2.3: Accreditation of quality of education programs (program internationally accredited) | 600,000 | 300,000 | - | 300,000 | 300,000 |
| | Program regionally accredited | | | | - | - |
| | Program nationally accredited | | | | - | - |
| | Program for self-evaluation | | | | - | - |
| | DLR 2.4: Collaboration and partnerships for applied research and training (MoU with public institutions/civil society) | 200,000 | 70,000 | - | 70,000 | 130,000 |
| | MoU with private sector/ industry | | | | - | - |
| | DLR 2.5: Peer-reviewed journals papers or peer-reviewed conference papers (paper accepted by a peer reviewed journal) | 300,000 | 300,000 | - | 300,000 | - |
| | Accepted peer-reviewed conference paper | | | | - | - |
| | DLR 2.6: Faculty and PhD student exchanges to promote regional research and teaching ("period" within the country) | 500,000 | - | - | - | 500,000 |
| | Exchange "period" within the region | | | | - | - |
| | Exchange "period" for international | | | | - | - |
| | DLR 2.7: External revenue generation (National level) | 900,000 | 223,703 | 675,697 | 899,400 | 600 |
| | External revenue generation (International level) | | | | - | - |
| | DLR 2.8: Institution participating in benchmarking exercise | 100,000 | 100,000 | - | 100,000 | - |
| DLI 3: Timely, transparent and institutionally reviewed Financial Management | DLR 3.1: Timely Withdrawal Application supported by financial reporting on the ACE account for the period | 75,000 | 15,000 | - | 15,000 | 60,000 |
| | DLR 3.2: Functioning Audit Committee under the university council | 75,000 | 15,000 | - | 15,000 | 60,000 |
| | DLR 3.3: Functioning internal audit unit for the university | 75,000 | 15,000 | - | 15,000 | 60,000 |
| | DLR 3.4: Transparency of financial management (audit reports, interim financial reports, budgets and annual work plan are all web accessible) | 75,000 | 15,000 | - | 15,000 | 60,000 |
| DLI 4 Timely and audited Procurement | DLR 4.1 Timely procurement audit report | 150,000 | 30,000 | - | 30,000 | 120,000 |
| | DLR4.2: Timely and satisfactory procurement progress report | 150,000 | 30,000 | - | 30,000 | 120,000 |
| Total in USD | | 6,000,000 | 2,807,703 | 675,697 | 3,483,400 | 2,516,600 |

Prepared by Dominique Nansana
Finance and Administration Director

Approved by BYANTHAXA MU
Accounting Officer





8. POLICIES AND PROCEDURES

The Accounting policies and Procedures of Pharm-biotechnology and Traditional Medicine center (PHARMBIOTRAC) are in accordance with the following;

- i) International Financial Reporting Standards,
- ii) The latest issue of the World Bank Financial Accounting Reporting and Audit Guidelines.

2. BASIS OF ACCOUNTING AND REPORTING

- i) The Accounting records and Financial Statements are prepared on a cash basis of accounting (in accordance with the International Public Sector Accounting Standards (IPSAS) issued by International Federation of Accountants (IFAC) and under the historical cost convention.
- ii) Financial transactions are recognized and recorded on cash basis.
- iii) Revenue is recognized when cash is received at the Bank of Uganda (BOU) and Standard Chartered Bank.
- iv) Project expenditures are recognized and recorded when payments are made to beneficiaries and not when the liabilities are created.
- v) Assets are expensed in full in the year of purchase, consistent with the cash basis of Accounting.

3. CURRENCIES

- i) Foreign currency transactions

The functional currency for PHARMBIOTRAC is the United States Dollars (US\$), and as much as possible, the records of receipts and payments for the project shall be maintained in US Dollars (US\$), which is the currency of the Grant. In particular transactions on IDA Designated Accounts will be maintained in United States dollars with Bank of Uganda as the Main account. Transactions made from Bank of Uganda to Standard chartered operational accounts are maintained in UGX and US Dollar.

Since the Grant is received in USD dollar, all transactions translated in Ugx shall maintain a same rate at the time of executing the transaction until the funds are fully exhausted of that rate provided by Bank of Uganda.

- ii) Local Currency

Where the project recognizes that some of the transactions may be effectively conducted in the local currency i.e. Uganda Shillings, the transaction values shall be translated into Dollars at the respective BOU exchange rates prevailing on the dates of those transactions. The resulting differences from the conversion and translation will be dealt with in the Sources and Uses of funds statement in the year in which they arise.

- iii) Exchange differences – gains and losses

Whenever realized, exchange gains on the Designated Account will be the benefit of Government of Uganda. Similarly, Government of Uganda will meet any realized exchange losses.